Cystic fibrosis (CF) lung disease is nowadays appreciated as a complex trait, characterised by dysfunction of the CF Transmembrane Conductor (CFTR) protein, opportunistic bacterial infections, chronic inflammation and remodelling of the airways. In this review, we have analysed the usefulness of biomarkers of inflammation and remodelling for their ability in predicting and assessing the onset of a pulmonary exacerbation, its evolution with time and its response to therapeutic interventions. Studies concerning sputum, bronchoalveolar lavage fluid, exhaled breath condensate and blood were considered. Our conclusions are: I) although their validity has been proven across different clinical settings, presently there is no biomarker which can be “promoted” to the status of surrogate end-point; II) longitudinal studies at different ages will be needed for assessing this issue; and III) different therapies should consider not only one biomarker but a constellation of them aiding in the evaluation of the complex pathogenesis of CF lung disease.

Biomarkers of inflammation and remodelling in cystic fibrosis / M. Conese, S.A. Tirelli, G. Alicandro, S. Di Gioia, A. Carbone, S. Castellani, C. Colombo. - In: CLINICAL IMMUNOLOGY, ENDOCRINE & METABOLIC DRUGS. - ISSN 2212-7070. - 3:2(2016), pp. 92-108. [10.2174/2212707004666170502171110]

Biomarkers of inflammation and remodelling in cystic fibrosis

G. Alicandro;C. Colombo
2016

Abstract

Cystic fibrosis (CF) lung disease is nowadays appreciated as a complex trait, characterised by dysfunction of the CF Transmembrane Conductor (CFTR) protein, opportunistic bacterial infections, chronic inflammation and remodelling of the airways. In this review, we have analysed the usefulness of biomarkers of inflammation and remodelling for their ability in predicting and assessing the onset of a pulmonary exacerbation, its evolution with time and its response to therapeutic interventions. Studies concerning sputum, bronchoalveolar lavage fluid, exhaled breath condensate and blood were considered. Our conclusions are: I) although their validity has been proven across different clinical settings, presently there is no biomarker which can be “promoted” to the status of surrogate end-point; II) longitudinal studies at different ages will be needed for assessing this issue; and III) different therapies should consider not only one biomarker but a constellation of them aiding in the evaluation of the complex pathogenesis of CF lung disease.
bronchoalveolar lavage; cystic fibrosis; cytokines; exhaled breath condensate; growth factors; oxidative stress; sputum
Settore MED/38 - Pediatria Generale e Specialistica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Biomarkers of inflammation and remodelling and inflammation in CF.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.11 MB
Formato Adobe PDF
2.11 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/551389
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact